Antibody Screening News and Research

RSS
Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

Gyros Protein Technologies introduces Gyrolab Generic Anti-AAV Kit to support gene therapy development

CDC releases new syphilis testing guidelines to combat rising cases

CDC releases new syphilis testing guidelines to combat rising cases

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

Universal screening: A game-changer in early detection and management of type 1 diabetes

Universal screening: A game-changer in early detection and management of type 1 diabetes

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

Artificial intelligence and polyclonal antibody sequencing redefine the future of antibody discovery

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

PhenomeX Launches Beacon Select™ Optofluidic System with Opto® B Discovery Workflows

Seroprevalence measurements reveal a higher incidence of asymptomatic SARS-CoV-2 infections among residents of three federal German states

Seroprevalence measurements reveal a higher incidence of asymptomatic SARS-CoV-2 infections among residents of three federal German states

Creoptix launches new WAVEcontrol software to deliver automated, flexible and intuitive label-free interaction analysis for biologics drug-discovery

Creoptix launches new WAVEcontrol software to deliver automated, flexible and intuitive label-free interaction analysis for biologics drug-discovery

LJI acquires Carterra LSA instrument to enhance antibody screening and characterization efforts

LJI acquires Carterra LSA instrument to enhance antibody screening and characterization efforts

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients

Real-world study shows Paxlovid associated with lower hospitalization rates

Real-world study shows Paxlovid associated with lower hospitalization rates

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

A clinical tool for monoclonal antibody allocation to treat COVID-19

A clinical tool for monoclonal antibody allocation to treat COVID-19

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Influenza vaccination does not affect risk of SARS-CoV-2 infection or COVID-19

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Scientists develop a high-throughput, cell-free screening platform for anti-SARS-CoV-2 antibody discovery

Researchers develop rapid antibody screening method for novel COVID-19 therapeutics development

Researchers develop rapid antibody screening method for novel COVID-19 therapeutics development

Study finds more children infected by coronavirus during the second wave in Germany

Study finds more children infected by coronavirus during the second wave in Germany

Study predicts good passive immunotherapy donors to combat COVID-19

Study predicts good passive immunotherapy donors to combat COVID-19

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

Chicago seroprevalence study shows COVID-19 cases 16 times higher than currently predicted

Novel approach can help measure antibodies against SARS-CoV-2

Novel approach can help measure antibodies against SARS-CoV-2

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.